Pharmacodynamics + Human molecular targets of<unk>  Target Affinity <unk> i) Ref(s) α1A-adrenergic 6.3 nM α1B-adrenergic 6.3 nM α1D-adrenergic 16 nM α2A-adrenergic 372 nM (HT29) α2B-adrenergic 199 nM α2C-adrenergic 159 nM (opossum) 5-HT1A 1,044–>10,000 nM 5-HT1B 2,515–6,300 nM 5-HT1D 32–>10,000 nM 5-HT1E >10,000 nM 5-HT1F 1.25–>10,000 nM<unk> A 0.20–9.8 nM<unk> B 200–3,236 nM<unk> C 17–186 nM 5-HT3 >10,000 nM (rodent) 5-HT4L 1,000 nM (rat) 5-HT5A 20,000 nM 5-HT5B 1,000–1,585 nM (rodent) 5-HT6 2,800 nM 5-HT7 320–1,334 nM D1 190–464 nM D2 >10,000 nM D3 ? D4 148 nM (canine) D5 2,500 nM H1 1.79 nM DAT >10,000 nM VMAT1 1,600 nM VMAT2 500 nM<unk>  is a high-affinity non-selective antagonist of<unk>  receptors in rodents, In addition to the<unk>  receptors,<unk>  is also a high affinity antagonist for the H1 receptor. It has also been found to block the vesicular monoamine transporter 2 (VMAT2). Pharmacokinetics The bioavailability of<unk>  is 50%. The plasma protein binding of<unk>  is 95.0% and it is mainly bound to albumin. The elimination half-life of<unk>  is 10 to 29 hours.
Ketanserin
Mianserin
Nabilone
Sumatriptan
Naratriptan
Triptan
Blonanserin
Zolmitriptan